/

Sociétés

Bi

Non vérifié

Biogen Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceManagement/Organisation d'EntrepriseMédecine Santé Bien-être

60 communiqués de presse

Voir tous les communiqués de presse

19/03/2026

Biotechnologie

Médecine Santé Bien-être

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Source

Émetteur

1.00

0

11/03/2026

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Source

Émetteur

1.00

0

05/03/2026

Biotechnologie

Médecine Santé Bien-être

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Source

Émetteur

1.00

0

04/03/2026

Biotechnologie

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Source

Émetteur

1.00

0

11/02/2026

Biotechnologie

Biogen Announces Board Chair Transition

Source

Émetteur

1.00

0

04/02/2026

Biotechnologie

Médecine Santé Bien-être

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Source

Émetteur

1.00

0

28/01/2026

Biotechnologie

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Source

Émetteur

1.00

0

12/01/2026

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Source

Émetteur

1.00

0

22/12/2025

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Source

Émetteur

1.00

0

05/12/2025

Biotechnologie

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0